Compare Occidental Petroleum Corporation (OXY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Occidental Petroleum Corporation vs Recursion Pharmaceuticals Inc — how do they compare? Occidental Petroleum Corporation trades at $61.23 (market cap $60.63B), while Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B). The key difference: Occidental Petroleum Corporation is far larger — about 32.6× Recursion Pharmaceuticals Inc's market cap, and Occidental Petroleum Corporation pays a 1.85% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| OXY | RXRX | |
|---|---|---|
Market Cap | $60.63B | $1.86B |
Sector | Energy | Health |
52-Week High | $66.24 | $6.79 |
52-Week Low | $38.92 | $2.84 |
Enterprise Value | $79.39B | $1.38B |
Dividend Yield | 1.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Occidental Petroleum (OXY) trades at $60.65, up 1.02% with strong technical momentum and bullish moving average signals. The company demonstrates robust profitability with 30.32% net income margin and 21.46% ROE, while trading at reasonable valuations (P/E 17.89, EV/EBITDA 5.59). Recent earnings beats and improving balance sheet with debt reduction to $25.32 billion support positive sentiment.
OXY presents a compelling opportunity with analyst consensus target of $68.67 (13% upside) and 50% buy ratings. Key catalysts include continued debt reduction, projected 2026 net margin expansion to 30.31%, and oil price tailwinds. Risks include oil price volatility, execution on production targets, and macroeconomic headwinds affecting energy demand.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
